Dyadic International (DYAI) Operating Expenses (2018 - 2026)
Dyadic International (DYAI) posted Operating Expenses of $3.0 million for Q1 2026, up 43.41% sequentially from $2.1 million in Q4 2025, and up 25.78% YoY from $2.4 million in Q1 2025.
Dyadic International (DYAI) Operating Expenses (2018 - 2026) Analysis & Trends
Dyadic International has reported Operating Expenses for 9 years, with the latest figure at $3.0 million in Q1 2026.
- Quarterly Operating Expenses rose 25.78% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (up 16.81% YoY) and the FY2025 annual result came in at $10.3 million, up 9.44% from the prior year.
- Operating Expenses improved to $3.0 million in Q1 2026 per DYAI's latest filing, from $2.1 million in the prior quarter.
- Over five years, Operating Expenses peaked at $4.0 million in Q2 2022 and troughed at $2.1 million in Q4 2025.
- A 5-year average of $2.8 million and a median of $2.7 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses plunged 99.91% in 2022, then soared 43.05% in 2025.
- Over 5 years, Operating Expenses stood at $3.0 million in 2022, then fell by 4.29% to $2.9 million in 2023, then declined by 17.78% to $2.3 million in 2024, then dropped by 10.48% to $2.1 million in 2025, then surged by 43.41% to $3.0 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $3.0 million, $2.1 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | 3.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.01 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Sep 30, 2025 | 3.09 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.40 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 2.43 Mn |
| Mar 31, 2024 | 2.46 Mn |
| Dec 31, 2023 | 2.86 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 3.13 Mn |
| Mar 31, 2023 | 3.03 Mn |
| Dec 31, 2022 | 2.98 Mn |
| Sep 30, 2022 | 2.74 Mn |
| Jun 30, 2022 | 3.98 Mn |
| Mar 31, 2022 | 3.39 Mn |
| Dec 31, 2021 | 4.53 Mn |
| Sep 30, 2021 | 4.02 Mn |
| Jun 30, 2021 | 4.80 Mn |